Ilk inhibitors for the treatment of renal disease

Abstract

The invention relates to the treatment of renal diseases using modulators of integrin linked kinase. Methods of treatment as well as therapeutic agents including antisense, small molecules, catalytic peptides and antibodies are disclosed. The agents of the invention may also be used in combination with traditional therapies for renal disease including ACE inhibitors. An advantage of the invention is that it treats one of the causes of renal disease, rather than just ameliorating symptoms, and can help prevent the progression of renal disease to the point of acute renal failure.

1 . A therapeutic composition for treating a patient with renal dysfunction comprising an effective dose of an integrin linked kinase (ILK) inhibitor.  
     
     
         2 . The composition of  claim 1 , wherein said ILK inhibitor is an antisense molecule specific for ILK.  
     
     
         3 . The composition of  claim 1 , wherein said ILK inhibitor is a peptide.  
     
     
         4 . The composition of  claim 1 , wherein said ILK inhibitor is a small organic compound.  
     
     
         5 . The composition of  claim 1 , wherein said ILK inhibitor is an antibody or fragment thereof.  
     
     
         6 . The composition of  claim 1 , wherein said ILK inhibitor is formulated for oral administration.  
     
     
         7 . The composition of  claim 1 , wherein said ILK inhibitor is formulated for intravenous administration.  
     
     
         8 . The composition of  claim 1 , wherein said ILK inhibitor is formulated for intraperitoneal administration.  
     
     
         9 . The composition of  claim 1 , wherein said ILK inhibitor is formulated for intraluminal administration.  
     
     
         10 . A method for treating a patient with renal dysfunction, the method comprising: 
 administering an effective dose of an ILK inhibitor to said patient.    
     
     
         11 . The method according to  claim 10 , wherein said inhibitor is a nucleic acid.  
     
     
         12 . The method according to  claim 11 , wherein said nucleic acid is an antisense molecule specific for ILK.  
     
     
         13 . The method of  claim 10 , wherein said ILK inhibitor is a peptide.  
     
     
         14 . The method of  claim 10 , wherein said ILK inhibitor is a small molecule of between 250 Daltons and 1000 Daltons molecular weight.  
     
     
         15 . The method of  claim 10 , wherein said ILK inhibitor is an antibody or fragment  
     
     
         16 . The method of  claim 10 , further comprising the step of: 
 administering an ACE inhibitor to said patient.    
     
     
         17 . A method for lowering the protein levels in urine, the method comprising: 
 administering an effective dose of an ILK inhibitor to said patient.    
     
     
         18 . The method according to  claim 17 , wherein said inhibitor is a nucleic acid.  
     
     
         19 . The method according to  claim 18 , wherein said nucleic acid is an antisense molecule specific for ILK.  
     
     
         20 . The method of  claim 17 , wherein said ILK inhibitor is a peptide.  
     
     
         21 . The method of  claim 17 , wherein said ILK inhibitor is a small organic compound.  
     
     
         22 . The method of  claim 17 , wherein said ILK inhibitor is an antibody or fragment  23 . The method of  claim 17 , further comprising the step of: 
 administering an ACE inhibitor to said patient.